LIU Jianping. Clinical research of traditional Chinese medicine for COVID-19: evidence, issues and challenges[J]. Modern Chinese Clinical Medicine, 2023, 30(4): 12-16.
DOI:
LIU Jianping. Clinical research of traditional Chinese medicine for COVID-19: evidence, issues and challenges[J]. Modern Chinese Clinical Medicine, 2023, 30(4): 12-16.DOI: 10.3969/j.issn.2095-6606.2023.04.003.
Clinical research of traditional Chinese medicine for COVID-19: evidence, issues and challenges
traditional Chinese medicine has been involved in the prevention and treatment for the viral disease since the beginning of the outbreak
and has made remarkable achievements. This study summarized the progress and existing problems of clinical research of traditional Chinese medicine for COVID-19
and proposed strategies for future TCM studies in case of public health emergency in relation to communicable diseases
to inform practice and policy. Evidence shows that traditional Chinese medicine has potential benefits in COVID-19 prevention
treatment and recovery
may help to reduce the infection rate of close contacts
reduce the viral load; improve the symptoms
relieve inflammation
reduce the rate of progression into severe cases
and shorten the time for viral clearance; improve gastrointestinal and respiratory symptoms and lung function in patients after COVID-19. Although large number of TCM studies on COVID-19 have been published
most of the evidence is of low quality. Therefore
more multi-center
large-sample
placebo-controlled
double-blind randomized controlled trials and related systematic reviews and meta-analyses are needed in the future.
关键词
Keywords
references
LUO H , TANG Q L , SHANG Y X , et al . Can Chinese medicine be used for prevention of Corona virus disease 2019 (COVID-19)? A review of historical classics,research evidence and current prevention programs [J/OL]. Chin J Integr Med , 2020 , 26 ( 4 ): 243 - 250 [ 2023-04-25 ]. https://pubmed.ncbi.nlm.nih.gov/32065348/ https://pubmed.ncbi.nlm.nih.gov/32065348/ .
LUO H , YANG M , TANG Q L , et al . Characteristics of registered clinical trials on traditional Chinese medicine for coronavirus disease 2019 (COVID-19):a scoping review [J/OL]. Eur J Integr Med , 2021 , 41 : 101251 [ 2023-04-25 ]. https://pubmed.ncbi.nlm.nih.gov/33204368/ https://pubmed.ncbi.nlm.nih.gov/33204368/ .
YANG M , SHANG Y X , TIAN Z Y , et al . Characteristics of registered studies for Coronavirus disease 2019 (COVID-19):a systematic review [J/OL]. Integr Med Res , 2020 , 9 ( 3 ): 100426 [ 2023-04-25 ]. https://pubmed.ncbi.nlm.nih.gov/32483523/ https://pubmed.ncbi.nlm.nih.gov/32483523/ .
LIU J , DONG F , ROBINSON N . State-of-the-art evidence of traditional Chinese medicine for treating coronavirus disease 2019 [J/OL]. Journal of Traditional Chinese Medical Sciences , 2022 , 9 ( 1 ): 5 [ 2023-04-25 ]. https://kns.cnki.net/kcms2/article/abstract?v=8xl4CyPd-wX4oObJLcr_YNwWCSEuGnENWyzqrTmiLa8lL1c_u_pnrdcl4O5p0fKpe6dE5uLbREj-So-1mZxWAxqoUZDoksbo94i2XaJA-utz_F1_MtbZAKRTBtc13Roc&uniplatform=NZKPT&language=gb https://kns.cnki.net/kcms2/article/abstract?v=8xl4CyPd-wX4oObJLcr_YNwWCSEuGnENWyzqrTmiLa8lL1c_u_pnrdcl4O5p0fKpe6dE5uLbREj-So-1mZxWAxqoUZDoksbo94i2XaJA-utz_F1_MtbZAKRTBtc13Roc&uniplatform=NZKPT&language=gb .
WU X , LI W , QIN Z , et al . Traditional Chinese medicine as an adjunctive therapy for mild and common COVID-19: a systematic review and network meta-analysis [J/OL]. Medicine (Baltimore) , 2021 , 100 ( 40 ): e27372 [ 2023-04-25 ]. https://pubmed.ncbi.nlm.nih.gov/34622839/ https://pubmed.ncbi.nlm.nih.gov/34622839/ .
LIANG S B , FANG M , LIANG C H , et al . Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: a rapid systematic review and meta-analysis of randomized controlled trials [J/OL]. Complement Ther Med , 2021 , 60 : 102744 [ 2023-04-25 ]. https://pubmed.ncbi.nlm.nih.gov/34091029/ https://pubmed.ncbi.nlm.nih.gov/34091029/ .
LIANG S B , ZHANG Y Y , SHEN C , et al . Chinese herbal medicine used with or without conventional western therapy for COVID-19: an evidence review of clinical studies [J/OL]. Front Pharmacol , 2021 , 11 : 583450 [ 2023-04-25 ]. https://pubmed.ncbi.nlm.nih.gov/33716720/ https://pubmed.ncbi.nlm.nih.gov/33716720/ .
SELVAKUMAR J , HAVDAL L B , DREVVATNE M , et al . Prevalence and characteristics associated with post-COVID-19 condition among nonhospitalized adolescents and young adults [J/OL]. JAMA Netw Open , 2023 , 6 ( 3 ): e235763 [ 2023-04-25 ]. https://pubmed.ncbi.nlm.nih.gov/36995712/ https://pubmed.ncbi.nlm.nih.gov/36995712/ .
SALAMANNA F , VERONESI F , MARTINI L , et al . Poste COVID-19 syndrome:the persistent symptoms at the post-viral stage of the disease. A systematic review of the current data [J/OL]. Front Med , 2021 , 8 : 653516 [ 2023-04-25 ]. https://pubmed.ncbi.nlm.nih.gov/34017846/ https://pubmed.ncbi.nlm.nih.gov/34017846/ .
AN X , PENG B , HUANG X , et al . Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized,double-blind,placebo-controlled multicenter trial [J/OL]. Chin Med , 2022 , 17 ( 1 ): 42 [ 2023-04-25 ]. https://pubmed.ncbi.nlm.nih.gov/35366928/ https://pubmed.ncbi.nlm.nih.gov/35366928/ .
CHAICHANA U , MAN KKC , CHEN A , et al . Definition of post-COVID-19 condition among published research studies [J/OL]. JAMA Netw Open , 2023 , 6 ( 4 ): e235856 [ 2023-04-25 ]. https://pubmed.ncbi.nlm.nih.gov/37017970/ https://pubmed.ncbi.nlm.nih.gov/37017970/ .
WORLD HEALTH ORGANIZATION . Pandemic influenza preparedness and response—WHO guidance document [EB/OL][ 2023-04-25 ]. https://www.who. int/influenza/resources/documents/pandemic_ guidance_04_2009/en/ https://www.who. int/influenza/resources/documents/pandemic_ guidance_04_2009/en/ .